Cristina Suárez

Hebron University — PS

Medicine · Health Sciences

54h-index14.1kcitations367works12.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(156), Cancer Genomics and Diagnostics(75), Renal and related cancers(63), Cancer Immunotherapy and Biomarkers(62), Bladder and Urothelial Cancer Treatments(45)

Publications363 total

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
UNC Libraries·2025Open Access
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
CA A Cancer Journal for Clinicians·2025Open Access
Organ tropism and tumor aggressiveness: A histology-driven view of metastatic urothelial carcinoma
European Urology Open Science·2025Open Access
Abstract 435: Evaluation of Latin American Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke: Systematic Review
Stroke Vascular and Interventional Neurology·2025Open Access
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial
Annals of Oncology·2025· 2 citedOpen Access
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum
The Journal of Urology·2025
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
The Lancet Oncology·2025· 4 citedOpen Access
26Subgroup analysis of the efficacy and safety of cabozantinib ± atezolizumab in patients from CONTACT-03 who received first-line treatment with immuno-oncology–based combinations
The Oncologist·2025Open Access
1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study
The Oncologist·2025· 1 citedOpen Access
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
Annals of Oncology·2025· 7 citedOpen Access
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
European Urology·2025· 4 cited
Úlceras y perforaciones gastroduodenales en migrantes tras la ruta atlántica en patera: experiencia clínica y terapéutica en un hospital terciario
2025
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
Clinical Genitourinary Cancer·2025
CUANDO LA AUTOMEDICACIÓN SUPONE UN RIESGO VITAL
2025
ABS0576 Safety and effectiveness of the use of combined therapy with bDMARDS and tsDMARDs in inmune-mediated inflammatory diseases
Annals of the Rheumatic Diseases·2025Open Access
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.
Journal of Clinical Oncology·2025
Ipilimumab/nivolumab versus standard of care in non-clear cell renal cancer: Results of the SUNNIFORECAST trial and potential role of the CPS score and tumor nephrectomy.
Journal of Clinical Oncology·2025
Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Journal of Clinical Oncology·2025
Efficacy and safety of second-line cabozantinib ± atezolizumab for patients with advanced renal cell carcinoma after progression on immuno-oncology combinations: Subgroup analysis of CONTACT-03.
Journal of Clinical Oncology·2025
Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC).
Journal of Clinical Oncology·2025
page 1 of 19Next →

Frequent Co-authors

Toni K. Choueiri(16), Robert J. Motzer(14), Thomas Powles(12), Bernard Escudier(11), Camillo Porta(8), Mahrukh Huseni(8), Brian I. Rini(8), Alain Ravaud(8), Jae‐Lyun Lee(8), Daniel Castellano(8), Carmen Peña(8), Mauricio Burotto(7), David F. McDermott(7), Michael B. Atkins(7), Sumanta K. Pal(7), Howard Gurney(7), Laurence Albigès(7), Fé Tubau(7), Thomas Powles(6), Yoshihiko Tomita(6)